ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
GraniteShares ETF Trust GraniteShares

GraniteShares ETF Trust GraniteShares (NVDL)

80,58
0,00
(0,00%)
Fermé 21 Novembre 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
80,58
Prix Achat
79,53
Prix Vente
79,66
Volume échangé
-
0,00 Fourchette du Jour 0,00
13,9294 Plage de 52 semaines 91,625
Clôture Veille
80,58
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
19 148 470
Volume financier
-
VWAP
-

NVDL Dernières nouvelles

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow FLEMINGTON, N.J., May 10 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) today announced that its...

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12 FLEMINGTON, N.J., MAY 3 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD: NVDL) , a leading formulator of...

NovaDel Pharma's Third Foreign Patent Issued

NovaDel Pharma's Third Foreign Patent Issued FLEMINGTON, N.J., April 22 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) said it was awarded Greek Patent No.GR0904055...

NovaDel CEO Interviews on Wall Street Reporter

NovaDel CEO Interviews on Wall Street Reporter First FDA Approval Filing to Occur Within Next Two Months; Five Tier One Drugs Entering Proof of Concept Studies FLEMINGTON, N.J., April 19...

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter FEMINGTON, N.J., April 15 /PRNewswire-FirstCall/ -- Gary Shangold, MD, chief executive officer of NovaDel Pharma, Inc. (BULLETIN...

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting FLEMINGTON, N.J., April 14 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD:...

NovaDel Reports First Quarter 2004 Progress

NovaDel Reports First Quarter 2004 Progress FLEMINGTON, N.J., Apr. 7 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) reported substantial progress in product development...

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board FLEMINGTON, N.J., March 1 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN...

NovaDel Raises $14 Million in Private Offering

NovaDel Raises $14 Million in Private Offering New Funding Will Accelerate Human Feasibility Studies of Four Top-Selling Drugs; First NDA Filing Scheduled for Q2-3 FLEMINGTON, N.J., Jan. 12...

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study FLEMINGTON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-2.44-2.9390508311383.0284.5671.411701267979.15130029SP
43.95.0860719874876.6885.6567.071551384477.81476089SP
1219.9132.816878193560.6785.6541.081914847064.66185434SP
2638.5291.583452211142.0691.62534.282163285163.64736917SP
5263.44852161370.36220789317.1314783991.62513.929426321411592457.86800099SP
15676.19841991739.062579274.381580191.6252.95186885748310556.91709616SP
26076.19841991739.062579274.381580191.6252.95186885748310556.91709616SP
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock